FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2146354558> ?p ?o ?g. }

• W2146354558 endingPage "632" @default.
• W2146354558 startingPage "622" @default.
• W2146354558 abstract "The role of ubiquitin-proteasome system in the accelerated atherosclerotic progression of diabetic patients is unclear. We evaluated ubiquitin-proteasome activity in carotid plaques of asymptomatic diabetic and nondiabetic patients, as well as the effect of rosiglitazone, a peroxisome proliferator–activated receptor (PPAR)-γ activator, in diabetic plaques. Plaques were obtained from 46 type 2 diabetic and 30 nondiabetic patients undergoing carotid endarterectomy. Diabetic patients received 8 mg rosiglitazone (n = 23) or placebo (n = 23) for 4 months before scheduled endarterectomy. Plaques were analyzed for macrophages (CD68), T-cells (CD3), inflammatory cells (HLA-DR), ubiquitin, proteasome 20S activity, nuclear factor (NF)-κB, inhibitor of κB (IκB)-β, tumor necrosis factor (TNF)-α, nitrotyrosine, matrix metalloproteinase (MMP)-9, and collagen content (immunohistochemistry and enzyme-linked immunosorbent assay). Compared with nondiabetic plaques, diabetic plaques had more macrophages, T-cells, and HLA-DR+ cells (P &lt; 0.001); more ubiquitin, proteasome 20S activity (TNF-α), and NF-κB (P &lt; 0.001); and more markers of oxidative stress (nitrotyrosine and O2− production) and MMP-9 (P &lt; 0.01), along with a lesser collagen content and IκB-β levels (P &lt; 0.001). Compared with placebo-treated plaques, rosiglitazone-treated diabetic plaques presented less inflammatory cells (P &lt; 0.01); less ubiquitin, proteasome 20S, TNF-α, and NF-κB (P &lt; 0.01); less nitrotyrosine and superoxide anion production (P &lt; 0.01); and greater collagen content (P &lt; 0.01), indicating a more stable plaque phenotype. Similar findings were obtained in circulating monocytes obtained from the two groups of diabetic patients and cultured in the presence or absence of rosiglitazone (7.0 μmol/l). Ubiquitin-proteasome over-activity is associated with enhanced inflammatory reaction and NF-κB expression in diabetic plaques. The inhibition of ubiquitin-proteasome activity in atherosclerotic lesions of diabetic patients by rosiglitazone is associated with morphological and compositional characteristics of a potential stable plaque phenotype, possibly by downregulating NF-κB-mediated inflammatory pathways." @default.
• W2146354558 created "2016-06-24" @default.
• W2146354558 creator A5007203413 @default.
• W2146354558 creator A5014570757 @default.
• W2146354558 creator A5014850119 @default.
• W2146354558 creator A5017394238 @default.
• W2146354558 creator A5019873610 @default.
• W2146354558 creator A5020924323 @default.
• W2146354558 creator A5022061577 @default.
• W2146354558 creator A5024433864 @default.
• W2146354558 creator A5033654738 @default.
• W2146354558 creator A5035071631 @default.
• W2146354558 creator A5035487463 @default.
• W2146354558 creator A5040984147 @default.
• W2146354558 creator A5041950779 @default.
• W2146354558 creator A5044764461 @default.
• W2146354558 creator A5052044111 @default.
• W2146354558 creator A5055583365 @default.
• W2146354558 creator A5056173815 @default.
• W2146354558 creator A5065723712 @default.
• W2146354558 creator A5077782340 @default.
• W2146354558 creator A5091616109 @default.
• W2146354558 date "2006-03-01" @default.
• W2146354558 modified "2023-10-17" @default.
• W2146354558 title "The Ubiquitin-Proteasome System and Inflammatory Activity in Diabetic Atherosclerotic Plaques" @default.
• W2146354558 cites W1851733051 @default.
• W2146354558 cites W1964527977 @default.
• W2146354558 cites W1974063618 @default.
• W2146354558 cites W1976257037 @default.
• W2146354558 cites W1982399072 @default.
• W2146354558 cites W1999855196 @default.
• W2146354558 cites W2009945135 @default.
• W2146354558 cites W2013824819 @default.
• W2146354558 cites W2014113220 @default.
• W2146354558 cites W2015753395 @default.
• W2146354558 cites W2015903618 @default.
• W2146354558 cites W2018995865 @default.
• W2146354558 cites W2025139724 @default.
• W2146354558 cites W2025624168 @default.
• W2146354558 cites W2042491008 @default.
• W2146354558 cites W2051625732 @default.
• W2146354558 cites W2087882379 @default.
• W2146354558 cites W2092881968 @default.
• W2146354558 cites W2101759139 @default.
• W2146354558 cites W2102267931 @default.
• W2146354558 cites W2106319388 @default.
• W2146354558 cites W2108521208 @default.
• W2146354558 cites W2121065969 @default.
• W2146354558 cites W2142541950 @default.
• W2146354558 cites W2145478166 @default.
• W2146354558 cites W2145510763 @default.
• W2146354558 cites W2148403865 @default.
• W2146354558 cites W2153876494 @default.
• W2146354558 cites W2157660001 @default.
• W2146354558 cites W2160234571 @default.
• W2146354558 cites W2163916220 @default.
• W2146354558 cites W2164367541 @default.
• W2146354558 cites W2165256339 @default.
• W2146354558 cites W2166895394 @default.
• W2146354558 cites W2178503716 @default.
• W2146354558 cites W2185461071 @default.
• W2146354558 cites W2324841714 @default.
• W2146354558 cites W2966952125 @default.
• W2146354558 cites W2975364463 @default.
• W2146354558 doi "https://doi.org/10.2337/diabetes.55.03.06.db05-0832" @default.
• W2146354558 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16505224" @default.
• W2146354558 hasPublicationYear "2006" @default.
• W2146354558 type Work @default.
• W2146354558 sameAs 2146354558 @default.
• W2146354558 citedByCount "107" @default.
• W2146354558 countsByYear W21463545582012 @default.
• W2146354558 countsByYear W21463545582013 @default.
• W2146354558 countsByYear W21463545582014 @default.
• W2146354558 countsByYear W21463545582015 @default.
• W2146354558 countsByYear W21463545582016 @default.
• W2146354558 countsByYear W21463545582017 @default.
• W2146354558 countsByYear W21463545582018 @default.
• W2146354558 countsByYear W21463545582021 @default.
• W2146354558 countsByYear W21463545582022 @default.
• W2146354558 countsByYear W21463545582023 @default.
• W2146354558 crossrefType "journal-article" @default.
• W2146354558 hasAuthorship W2146354558A5007203413 @default.
• W2146354558 hasAuthorship W2146354558A5014570757 @default.
• W2146354558 hasAuthorship W2146354558A5014850119 @default.
• W2146354558 hasAuthorship W2146354558A5017394238 @default.
• W2146354558 hasAuthorship W2146354558A5019873610 @default.
• W2146354558 hasAuthorship W2146354558A5020924323 @default.
• W2146354558 hasAuthorship W2146354558A5022061577 @default.
• W2146354558 hasAuthorship W2146354558A5024433864 @default.
• W2146354558 hasAuthorship W2146354558A5033654738 @default.
• W2146354558 hasAuthorship W2146354558A5035071631 @default.
• W2146354558 hasAuthorship W2146354558A5035487463 @default.
• W2146354558 hasAuthorship W2146354558A5040984147 @default.
• W2146354558 hasAuthorship W2146354558A5041950779 @default.
• W2146354558 hasAuthorship W2146354558A5044764461 @default.
• W2146354558 hasAuthorship W2146354558A5052044111 @default.
• W2146354558 hasAuthorship W2146354558A5055583365 @default.
• W2146354558 hasAuthorship W2146354558A5056173815 @default.

• next